Literature DB >> 12165213

Systemic sclerosis-scleroderma.

U-F Haustein1.   

Abstract

Systemic sclerosis is a clinically heterogeneous, systemic disorder which affects the connective tissue of the skin, internal organs and the walls of blood vessels. It is characterized by alterations of the microvasculature, disturbances of the immune system and by massive deposition of collagen and other matrix substances in the connective tissue. This review discusses epidemiology and survival, clinical features including subsets and internal organ involvement, pathophysiology and genetics, microvasculature, immunobiology, fibroblasts and connective tissue metabolism and environmental factors. Early diagnosis and individually tailored therapy help to manage this disorder, which is treatable, but not curable. Therapy involves immunomodulation as well as the targeting of blood vessel mechanics and fibrosis. Physical therapy and psychotherapy are also important adjunctive therapies in this multifactorial disease.

Entities:  

Mesh:

Year:  2002        PMID: 12165213

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  18 in total

1.  Renal disease in systemic sclerosis with normal serum creatinine.

Authors:  Reem H A Mohamed; Hania S Zayed; Amr Amin
Journal:  Clin Rheumatol       Date:  2010-02-23       Impact factor: 2.980

2.  Association between 'interleukin' 10 gene (IL10) polymorphisms and systemic sclerosis with interstitial lung involvement.

Authors:  O Ates; B Müsellim; G Ongen; A Topal-Sarikaya
Journal:  Rheumatol Int       Date:  2008-05-21       Impact factor: 2.631

Review 3.  Cytokines in the immunopathology of systemic sclerosis.

Authors:  Jasmin Raja; Christopher Paul Denton
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

4.  Tc-99m diethylenetriamine pentaacetic acid (DTPA) renal function reserve estimation: is it a reliable predictive tool for assessment of preclinical renal involvement in scleroderma patients?

Authors:  Amr Amin; S El-Sayed; N Taher; M Sedki; H Nasr
Journal:  Clin Rheumatol       Date:  2012-02-24       Impact factor: 2.980

5.  Evaluation of liver function tests in scleroderma patients.

Authors:  Gehan Ibrahim Abdelrazek Salem; Awni Ali Abdulrahman
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

6.  Mucocutaneous and demographic features of systemic sclerosis: a profile of 46 patients from eastern India.

Authors:  Sudip Kumar Ghosh; Debabrata Bandyopadhyay; Indranil Saha; Jayanta Kumar Barua
Journal:  Indian J Dermatol       Date:  2012-05       Impact factor: 1.494

7.  Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic sclerosis.

Authors:  K Skretkowicz; J Skretkowicz; B Gawrońska-Szklarz; W Górnik; M Rychlik-Sych; A Sysa-Jedrzejowska
Journal:  Eur J Clin Pharmacol       Date:  2004-11-24       Impact factor: 2.953

8.  Decreased interleukin-20 expression in scleroderma skin contributes to cutaneous fibrosis.

Authors:  Hideo Kudo; Masatoshi Jinnin; Yoshihide Asano; Maria Trojanowska; Wakana Nakayama; Kuniko Inoue; Noritoshi Honda; Ikko Kajihara; Katsunari Makino; Satoshi Fukushima; Hironobu Ihn
Journal:  Arthritis Rheumatol       Date:  2014-06       Impact factor: 10.995

9.  The use of streptolysin o for the treatment of scars, adhesions and fibrosis: initial investigations using murine models of scleroderma.

Authors:  Stephen W Mamber; Vit Long; Ryan G Rhodes; Sunthorn Pond-Tor; Lyn R Wheeler; Kellie Fredericks; Brian Vanscoy; Jean-Frederic Sauniere; Remy Steinschneider; Jean-Claude Laurent; John McMichael
Journal:  Nonlinearity Biol Toxicol Med       Date:  2004-04

10.  Serum antioxidant status in patients with systemic sclerosis.

Authors:  Iffat Hassan; Peerzada Sajad; Sabiya Majid; Tehseen Hassan
Journal:  Indian J Dermatol       Date:  2013-05       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.